BIOMAT Database Logo BIOMAT Database Logo

Anti-HIV agents: design and discovery of new potent RT inhibitors. 2003

Maria Letizia Barreca, and Alba Chimirri, and Erik De Clercq, and Laura De Luca, and Anna-Maria Monforte, and Pietro Monforte, and Angela Rao, and Maria Zappalà
Dipartimento Farmaco-Chimico, Università degli Studi di Messina, Viale Annunziata, 98168 Messina, Italy.

This paper reports our work in the field of nonnucleoside RT inhibitors (NNRTIs). On the basis of extensive studies on 1H,3H-thiazolo[3,4-a]benzimidazole derivatives (TBZs) followed by structure-activity relationship (SAR) considerations and molecular modeling, the design and synthesis of a series of 2,3-diaryl-1,3-thiazolidin-4-ones have been performed. Some derivatives proved to be highly effective in inhibiting human immunodeficiency virus type-1 (HIV-1) replication at nanomolar concentrations with minimal toxicity, acting as reverse transcriptase (RT) inhibitors. Computational studies were used in order to probe the binding of our ligands to HIV-1-RT.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013678 Technology, Pharmaceutical The application of scientific knowledge or technology to pharmacy and the pharmaceutical industry. It includes methods, techniques, and instrumentation in the manufacture, preparation, compounding, dispensing, packaging, and storing of drugs and other preparations used in diagnostic and determinative procedures, and in the treatment of patients. Technology, Pharmacy,Pharmaceutic Technology,Pharmaceutical Technology,Pharmacy Technology,Technology, Pharmaceutic
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Maria Letizia Barreca, and Alba Chimirri, and Erik De Clercq, and Laura De Luca, and Anna-Maria Monforte, and Pietro Monforte, and Angela Rao, and Maria Zappalà
Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer's Agents Based on Rational Design.
March 2017, Journal of medicinal chemistry,
Maria Letizia Barreca, and Alba Chimirri, and Erik De Clercq, and Laura De Luca, and Anna-Maria Monforte, and Pietro Monforte, and Angela Rao, and Maria Zappalà
Discovery of New Potent anti-MERS CoV Fusion Inhibitors.
January 2021, Frontiers in pharmacology,
Maria Letizia Barreca, and Alba Chimirri, and Erik De Clercq, and Laura De Luca, and Anna-Maria Monforte, and Pietro Monforte, and Angela Rao, and Maria Zappalà
Computer-aided design and discovery of protein-protein interaction inhibitors as agents for anti-HIV therapy.
January 2014, SAR and QSAR in environmental research,
Maria Letizia Barreca, and Alba Chimirri, and Erik De Clercq, and Laura De Luca, and Anna-Maria Monforte, and Pietro Monforte, and Angela Rao, and Maria Zappalà
Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer's Agents by Structure-Based Design.
September 2019, Journal of medicinal chemistry,
Maria Letizia Barreca, and Alba Chimirri, and Erik De Clercq, and Laura De Luca, and Anna-Maria Monforte, and Pietro Monforte, and Angela Rao, and Maria Zappalà
New AZT conjugates as potent anti-HIV agents.
January 2006, Nucleosides, nucleotides & nucleic acids,
Maria Letizia Barreca, and Alba Chimirri, and Erik De Clercq, and Laura De Luca, and Anna-Maria Monforte, and Pietro Monforte, and Angela Rao, and Maria Zappalà
Design of potential anti-HIV agents. 1. Mannosidase inhibitors.
September 1989, Journal of medicinal chemistry,
Maria Letizia Barreca, and Alba Chimirri, and Erik De Clercq, and Laura De Luca, and Anna-Maria Monforte, and Pietro Monforte, and Angela Rao, and Maria Zappalà
Design and development of integrase inhibitors as anti-HIV agents.
September 2003, Current medicinal chemistry,
Maria Letizia Barreca, and Alba Chimirri, and Erik De Clercq, and Laura De Luca, and Anna-Maria Monforte, and Pietro Monforte, and Angela Rao, and Maria Zappalà
Discovery of novel small molecule TLR4 inhibitors as potent anti-inflammatory agents.
June 2018, European journal of medicinal chemistry,
Maria Letizia Barreca, and Alba Chimirri, and Erik De Clercq, and Laura De Luca, and Anna-Maria Monforte, and Pietro Monforte, and Angela Rao, and Maria Zappalà
Discovery of potent and orally active MTP inhibitors as potential anti-obesity agents.
June 2006, Bioorganic & medicinal chemistry letters,
Maria Letizia Barreca, and Alba Chimirri, and Erik De Clercq, and Laura De Luca, and Anna-Maria Monforte, and Pietro Monforte, and Angela Rao, and Maria Zappalà
Pyrimidine 2,4-Diones in the Design of New HIV RT Inhibitors.
May 2019, Molecules (Basel, Switzerland),
Copied contents to your clipboard!